Determinants of Persistence and Recovery of Chronic COVID19 Chemosensory Dysfunction

In 2-4% of patients, COVID19 chemosensory dysfunction (CSD) persists beyond six months, accounting for up to 4 million people in the US. The predictors of persistence and recovery require further exploration.